GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tharimmune Inc (NAS:THAR) » Definitions » Total Current Liabilities

Tharimmune (Tharimmune) Total Current Liabilities : $1.84 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Tharimmune Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Tharimmune's total current liabilities for the quarter that ended in Mar. 2024 was $1.84

Tharimmune Total Current Liabilities Historical Data

The historical data trend for Tharimmune's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tharimmune Total Current Liabilities Chart

Tharimmune Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
1.13 2.73 4.53 1.15 1.82

Tharimmune Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.52 1.53 1.41 1.82 1.84

Tharimmune Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Tharimmune's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.815+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=1.82

Tharimmune's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.521+0
+Other Current Liabilities+Current Deferred Liabilities
=0.317+0
=1.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Tharimmune Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Tharimmune's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Tharimmune (Tharimmune) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tharimmune Inc (NAS:THAR) » Definitions » Total Current Liabilities
Comparable Companies
SLRX NVIV HSTC PHIO SNPX IVBT ARTH CWBR ADIL SPRC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
1200 Route 22 East, Suite 2000, Bridgewater, NJ, USA, 08807
Website
https://www.hillstreambio.com
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors.
Executives
Randy Milby director, officer: Chief Executive Officer 5 JACK LANE, NEWARK DE 19711
Kelly Anderson director C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
Leonard L Mazur director C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Sandeep Laumas 10 percent owner 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Thomas Hess officer: Chief Financial Officer 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Sireesh Appajosyula director 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Lynne A. Bui director 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Surender Kharbanda 10 percent owner 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Highpoint Pharmaceuticals Llc 10 percent owner 16192 COASTAL HIGHWAY, LEWES DE 19958
Kufe Llc 10 percent owner 179 GROVE STREET, WELLESLEY MA 02482
Varinder Kaur 10 percent owner 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807

Tharimmune (Tharimmune) Headlines

From GuruFocus

Hillstream BioPharma to Participate in Two Major Industry Conferences in April 2023

By sperokesalga sperokesalga • 03-28-2023

Hillstream BioPharma Announces Proposed Public Offering

By sperokesalga sperokesalga • 04-27-2023

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

By Marketwired • 07-20-2023

In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer

By sperokesalga sperokesalga • 02-10-2023

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

By sperokesalga sperokesalga • 05-15-2023

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

By ACCESSWIRE • 09-22-2023

Hillstream BioPharma Announces Closing of Public Offering of Common Stock

By sperokesalga sperokesalga • 05-02-2023

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias

By Stock market mentor Stock market mentor • 02-08-2023

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

By sperokesalga sperokesalga • 02-15-2023

Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences

By sperokesalga sperokesalga • 05-02-2023